目的 探讨痛风伴高尿酸血症患者应用非布司他治疗的效果及对生命质量评分(quality of life,QOL)的影响。方法 选择2017-03至2018-03在医院接受治疗的痛风伴高尿酸血症患者110例进行对比调查,其中55例采用别嘌醇治疗作为对照组,另外55例采用非布司他治疗作为观察组,比较两组患者治疗效果。结果 观察组55例均达到有效及以上治疗效果,总有效率为100.00%;对照组6例无效,总有效率为89.09%,治疗之前,两组患者在尿酸水平上进行对比并无明显差异;治疗后,观察组尿酸平均水平为(352.26±5.47)μ/L,明显低于对照组的(368.25±5.46)μmol/L;观察组治疗期间仅有1例出现恶心,不良反应发生率为1.82%,对照组有8例发生转氨酶升高、肝功能异常、恶心,不良反应发生率为14.55%;观察组QOL评分达到良好及较好的患者比例明显高于对照组。结论 非布司他对于痛风伴随高尿酸血症患者治疗效果优于别嘌呤醇,且有助于提升患者生命质量评分。

Objective To investigate the effect of non-budastatin therapy on the quality of life (QOL) of gout patients with hyperuricemia.Methods One hundred and ten patients with gout and hyperuricemia treated in our hospital were randomly selected for a comparative investigation. Half of these patients were treated with allopurinol and served as the control group, and the rest were treated with febuxostat as the observation group.Results All the patients in the observation group were treated effectively and the total effective rate was 100.00%. The therapeutic effect was poor in six cases in the control group, with a total effective rate of 89.09%. There was no significant difference in uric acid levels between the two groups before treatment. After treatment, the average level of uric acid in the observation group was (352.26±5.47)μmol/L, significantly lower than (368.25±5.46)μmol/L in the control group. Only one patient in the observation group had nausea during treatment, and the incidence of adverse reactions was 1.82%. In the control group, 8 patients had elevated transaminase, abnormal liver function and nausea during treatment, and the incidence of adverse reactions was 14.55%. The proportion of patients with good QOL scores in the observation group was significantly higher than that in the control group.Conclusions Feibusta is superior to allopurinol in the treatment of gout with hyperuricemia and helps to improve the quality of life of patients.